Dudediligence.

Compass Therapeutics, Inc

CMPXNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

180.1M

on 2026-06-30, from 137.6M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

50M100M150MMar2024JunSepDecMar2025JunSep$3.00DecMar2026Jun

Newest

$100.0M

S-3 of 2025-12-30. Sales under the at-the-market programme filed with it are not stated apart. S-3 ↗

$100.0M

Leerink Partners, agreement of 2025-12-30. No at-the-market sales statement read from a 10-Q or 10-K. S-3 ↗

Warrants

The 10-Q filed 2026-08-06 is not read yet.

Cash

12.8 quarters

$179.9M on 2026-06-30 ÷ $14.0M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
DateWhatSharesPriceGrossFiling
2025-08-12Public offering incl. 6.71M pre-funded40,000,000$3.00$120.0M424B5 ↗